Cellular Health Screening Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Cellular Health Screening Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The cellular health screening market is expected to register a CAGR of 8.7% over the forecast period.

COVID-19 has had a significant impact on the growth of the market over the study period. The rise in preventive health awareness among the global population during the pandemic drives the market's growth. According to the NCBI article published in June 2022, the most common tests performed in the past 12 months were 83% of blood pressure measurements, 66.2% of blood sugar, 53.1% of urinalysis, and 55.1% of the liquid panel. The high number of preventive health screenings during the pandemic is expected to contribute to the growth of the market. In addition, the demand for cellular health screening is expected to remain undisturbed during the post-pandemic period owing to the rising preference for preventive healthcare, thereby contributing to the growth of the market over the next five years.

The growth of the market is attributed to rising applications of cellular health screening in personalized medicine and increasing government focus on preventive healthcare. The potential applications of cellular health screening in personalized medicine have provided significant growth opportunities to market players in this field. Along with the rapidly growing geriatric population, the demand for cellular screening is expected to rise during the forecast period. According to the United Nations Department of Economics and Social 2022 report, there were 771 million people aged 65 years or over globally in 2022, and the older population is projected to reach 994 million by 2030 and 1.6 billion by 2050. The growing geriatric population is more prone to chronic diseases, and thus, this increases the demand for preventive diagnostics, particularly cellular health screening.

Furthermore, the rising focus of the government on preventive care is expected to boost market growth further. For instance, in November 2022, the government of Haryana launched a mobile health screening initiative. The screening services include tests such as blood analysis, urine analysis, and HBA1C testing, among others. Such initiatives will lead to increased adoption of cellular health screening, driving the market growth.

Rising initiatives from the key market players are also expected to drive the cell health screening market. For instance, in November 2021, Menarini Silicon Biosystems commercially launched the CELL SEARCH laboratory-developed test for the enumeration of circulatory multiple myeloma cells for non-invasive monitoring of disease from whole blood. Such launches will therefore lead to increased adoption of cellular health screening tests, bolstering the market growth.

Thus, the above-mentioned factors are expected to drive the growth of the market over the forecast period. However, the risks associated with the transport of samples are expected to restrain the growth during the forecast period.

The telomere test for a significant share of the cellular health screening market as these panels are used to get more accurate information and help perform cellular health screening tests to measure the length of the telomere, thereby preventing diseases. Furthermore, with the rising geriatric population, the preference for telomere tests is expected to rise as it facilitates individuals to check their cellular age and thereby take preventive measures, contributing to the growth of the market.

According to the Frontiers research study published in January 2021, telomere had been the most widely used molecular biomarker of aging. Innovative approaches, such as single-cell telomere measurement techniques aimed at the identification of critically short telomeres and DNA methylation-based methods of telomere length estimation, were being developed to improve the sensitivity, repeatability, and throughputs of methods. Such uses of telomere-based tests and developments of improved sensitivity telomere tests are expected to contribute to the growth of the segment over the forecast period.

The rise in the market player's activities, such as product launches, to meet the growing demand for telomere tests is expected to contribute to the segment's growth. For instance, in August 2021, TruDiagnostics released a new report expansion for TruAge, its epigenetic testing service. This expansion gives an accurate estimation of telomere length based on methylation. Thus, the above-mentioned factors are expected to contribute to the growth of the segment over the forecast period.

Therefore, factors such as innovations in telomere tests and rising initiatives by key players for the launch of telomere tests are expected to drive segment growth.

North America is expected to hold a significant share of the cellular health screening market owing to a high patient pool and rising disease prevalence.

According to the American Cancer Society, in 2022 estimated that a total of 1.9 million new cancer cases would occur in the United States in 2022. Such increasing incidence of chronic diseases among the population is expected to drive the demand for cellular health screening owing to the effective and early diagnosis, thereby contributing to the growth of the market.

In addition, the Centres for Disease Control and Prevention (CDC) data updated in July 2022 showed that coronary heart disease was the most common type of heart disease, and approximately 20.1 million adults of age 20 and older had the disease in the United States. As per the CDC data in October 2022, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of cellular health screening for early diagnosis, driving the market's growth.

Furthermore, in June 2021, Grail launched a single blood test capable of detecting the presence of multiple cancers with the Galleri diagnostic. The test is meant to screen people who may already have an elevated risk for cancer, such as adults over the age of 50. such initiatives from the key market players lead to increased adoption of cellular health screening in the region, driving market growth.

The cellular health screening market is fragmented due to the presence of several companies operating globally as well as regionally. The factors owing to the competition include the rise in the launch of innovative cellular screening tests by key market players and key strategies adopted by the companies, among others. Some of the players in the market include Bio-Reference Laboratories Inc., Genova Diagnostics, Immundiagnostik AG, Quest Diagnostics, SpectraCell Laboratories Inc., and Telomere Diagnostics Inc., among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support